News Release

ATS Foundation/Boehringer Ingelheim Pharmaceuticals Inc. research fellowship in idiopathic pulmonary fibrosis

Grant and Award Announcement

American Thoracic Society

(New York, NY) - April 8, 2019 - Paul Andrew Reyfman, MD, MS, of Northwestern University has been awarded the ATS Foundation/Boehringer Ingelheim Pharmaceuticals, Inc. Research Fellowship in idiopathic pulmonary fibrosis.

The $100,000 award will help fund Dr. Reyfman's research, "Single Cell Transcriptomic Analysis of Pulmonary Fibrosis."

Idiopathic pulmonary fibrosis (IPF) is a rare and serious lung disease where an unknown factor causes permanent scarring of the lungs. It affects as many as 132,000 Americans, typically men over the age of 65. Symptoms of IPF include breathlessness, persistent dry cough and fatigue. Diagnosing IPF can be difficult and take years because the symptoms of IPF are similar to and often confused with more common respiratory diseases like COPD and asthma.

"While we have made significant progress in understanding the clinical management of idiopathic pulmonary fibrosis through several clinical trials over the last 25 years , the need to abort the disease progression and improve outcomes that are meaningful for the patients - their ability to function and lessen their symptoms , improve quality of life and enhance survival -- can only be accomplished by collective efforts of all concerned with continued research," said Ganesh Raghu, MD, professor of Medicine and Laboratory Medicine, and director of Center for ILD , University of Washington, Seattle.

He added: "The ATS Foundation/Boehringer Ingelheim Pharmaceuticals Inc. Research Fellowship in Idiopathic Pulmonary Fibrosis awarded to Paul Andrew Reyfman, MD, MS, is well-deserved. His proposed research on Single Cell Transcriptomic Analysis of Pulmonary Fibrosis is novel. I look forward to the results of this research that will hopefully lead to molecular means to diagnose early on, as well as studies that will predict prognosis and outcomes for patients with IPF and fibrotic lung diseases."

"We are proud to support ATS on this unique award to advance innovative technologies that will lead to more accurate diagnoses and better predictions of treatment response," said Craig Conoscenti, MD, FCCP, ATSF, medical expert, Interstitial Lung Disease, Clinical Development and Medical Affairs at Boehringer Ingelheim Pharmaceuticals, Inc. "This research award builds on our 100-year heritage in respiratory disease and offers another opportunity for our company to continue to improve care for those living with IPF."


About the ATS Foundation

Since its inception, the ATS Foundation Research Program has awarded $19.3 million to 263 investigators, both in the U.S. and internationally. These researchers have gone on to receive $330 million in federal funding. That's a return on investment of $17 per dollar awarded. You can learn more about our most recent awardees here.

About Boehringer Ingelheim Pharmaceuticals

Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, Conn., is the largest U.S. subsidiary of Boehringer Ingelheim Corporation.

Boehringer Ingelheim is one of the world's top 20 pharmaceutical companies. Headquartered in Ingelheim, Germany, the company operates globally with approximately 50,000 employees. Since its founding in 1885, the company has remained family-owned and today creates value through innovation for three business areas including human pharmaceuticals, animal health and biopharmaceutical contract manufacturing.

Boehringer Ingelheim is committed to improving lives and providing valuable services and support to patients and their families. Our employees create and engage in programs that strengthen our communities. Please visit to learn more about how we make more health through our Corporate Social Responsibility initiatives.

For more information please visit, or follow us on Twitter @BoehringerUS.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.